Wall Street analysts forecast that Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) will report earnings per share of ($0.15) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Cyclacel Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate coming in at ($0.16). Cyclacel Pharmaceuticals posted earnings per share of ($0.16) in the same quarter last year, which would indicate a positive year over year growth rate of 6.3%. The firm is expected to report its next earnings results after the market closes on Tuesday, August 13th.
On average, analysts expect that Cyclacel Pharmaceuticals will report full year earnings of ($0.63) per share for the current fiscal year, with EPS estimates ranging from ($0.68) to ($0.57). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.59) per share, with EPS estimates ranging from ($0.59) to ($0.58). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Cyclacel Pharmaceuticals.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.04.
CYCC has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating on shares of Cyclacel Pharmaceuticals in a report on Wednesday, May 15th. Roth Capital reissued a “buy” rating on shares of Cyclacel Pharmaceuticals in a report on Thursday, May 23rd. Finally, Zacks Investment Research downgraded Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Cyclacel Pharmaceuticals has an average rating of “Buy” and an average price target of $5.00.
An institutional investor recently raised its position in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC lifted its position in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 82.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,102,400 shares of the biotechnology company’s stock after buying an additional 498,200 shares during the period. Renaissance Technologies LLC owned about 6.41% of Cyclacel Pharmaceuticals worth $596,000 as of its most recent SEC filing. 5.36% of the stock is owned by institutional investors and hedge funds.
Shares of CYCC traded down $0.05 on Thursday, hitting $0.45. The company’s stock had a trading volume of 3,051 shares, compared to its average volume of 73,454. The firm has a market capitalization of $9.29 million, a P/E ratio of -0.72 and a beta of 2.98. The company has a quick ratio of 8.09, a current ratio of 8.09 and a debt-to-equity ratio of 0.08. Cyclacel Pharmaceuticals has a fifty-two week low of $0.51 and a fifty-two week high of $1.87. The business has a 50 day moving average price of $0.56.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.
Featured Article: Hedge Funds Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.